Nexalis Therapeutics Limited (ASX:NX1)

Nexalis Therapeutics Ratios and Metrics

Market cap in millions AUD. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 2, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	6	6	7	6	11	15
Market Cap Growth	14.95%	-23.11%	35.75%	-51.02%	-25.89%	46.10%
Enterprise Value	7	6	7	5	9	12
Last Close Price	0.03	0.02	0.03	0.03	0.06	0.09
PS Ratio	8.24	7.48	18.59	4.57	453.06	83.43
PB Ratio	-5.38	-4.89	-116.79	8.27	5.91	5.66
P/TBV Ratio	-	-	-	8.27	5.95	5.69
EV/Sales Ratio	8.64	7.29	18.56	4.21	376.75	64.44
Debt / Equity Ratio	-0.63	-0.63	-0.53	0.84	-	-
Net Debt / Equity Ratio	-0.26	-0.26	2.52	-0.23	-1.12	-1.05
Net Debt / EBITDA Ratio	-	-	-	0.11	1.10	2.53
Net Debt / FCF Ratio	-0.34	-0.34	0.44	0.08	1.16	2.42
Asset Turnover	0.80	0.80	0.35	0.63	0.01	0.08
Inventory Turnover	-	-	-	-	-	11.19
Quick Ratio	0.55	0.55	0.83	1.67	6.09	11.14
Current Ratio	0.59	0.59	0.92	1.73	6.32	11.48
Return on Equity (ROE)	-	-	-402.12%	-112.39%	-84.14%	-55.53%
Return on Assets (ROA)	-110.17%	-110.17%	-69.85%	-46.40%	-47.07%	-28.73%
Return on Capital Employed (ROCE)	197.20%	197.20%	2010.10%	-213.80%	-102.70%	-41.50%
Earnings Yield	-28.92%	-31.84%	-16.19%	-26.23%	-17.15%	-7.33%
FCF Yield	-	-15.46%	-4.94%	-35.65%	-16.43%	-7.65%
Buyback Yield / Dilution	-1.06%	-1.06%	-12.72%	-9.42%	-3.27%	-68.94%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.